The FMC | Calcium Channel Blocker

Main ideas / lessons conveyed

• Calcium channel blocker (CCB) drugs are medications used not only for hypertension, but also for several cardiovascular conditions, including:
  • Tachycardia / fast heart rate
  • Other irregular heart rhythm disorders
  • Blood vessel disorders

Core physiology: how calcium drives contraction and heart electrical activity

• Calcium ions enter cells through calcium channels.

• A heart/blood vessel scenario described:

  • Adrenaline binds to its receptor
  • This leads to opening ion channels and electrical changes driven by charged ions:
    • Sodium in
    • Potassium out
    • Calcium in

• Two-step calcium concept in muscle cells

  • Electrical/trigger calcium
    • The initial calcium event that affects electrical activity in the heart.
  • Contraction calcium
    • Calcium is released/stored in the sarcoplasmic reticulum
    • Calcium binds troponin, freeing actin–myosin interaction → contraction

• The video’s emphasis: CCBs block calcium’s movement/availability, which can reduce:

  • Heart electrical/contractile behavior (depending on the subtype)
  • Smooth muscle contraction in blood vessels → vessel dilation

---

Methodology / classification framework presented

A) Classification of calcium channel blockers into two groups

1) Dihydropyridines (DHP-CCBs)

• Examples listed

  • Nifedipine
  • Nicardipine
  • Amlodipine
  • Also mentioned: Clevidipine
  • Mentioned as newer/less available: Lercanidipine

• Mechanism (as described)

  • Inhibit the calcium step related to the sarcoplasmic reticulum process
  • Reduce calcium available for contraction
  • Greater effect on blood vessels

• Clinical emphasis

  • More focused on blood vessels
  • Commonly used for hypertension and blood vessel disorders

2) Non-dihydropyridines

• Examples listed

  • Diltiazem
  • Verapamil

• Mechanism (as described)

  • Inhibit calcium handling with a more direct action on the heart

• Clinical emphasis

  • Used in heart disorders, especially tachycardia / increased heart pump rate

---

B) Functional differences described between groups

• Non-dihydropyridines
  • More cardiac effect
  • Intended to slow/affect heart rate (noted for tachycardia use)

Pharmacokinetic point (as described)

- **Verapamil**: **first-pass metabolism** → lower bioavailability (~**25–30%** mentioned)
- **Diltiazem**: less first-pass metabolism → higher bioavailability (~**40–60%** mentioned)

• Dihydropyridines
  • More vascular effect → vasodilation

---

C) Generation-by-generation points for key dihydropyridines

Nifedipine

• Fast onset and short duration (~2–3 hours mentioned)
• Often associated with reflex tachycardia, so it’s less favored for routine use
• Immediate-release formulations were highlighted as riskier

Amlodipine

• Described as third generation
• Long duration (about 30–50 hours mentioned)
• Can be used once daily
• Mentioned benefit:
  • May reduce stroke risk (as claimed in the video)

Lercanidipine

• Described as newest generation
• Better/selective for blood vessels
• Lower risk of edema (swelling) mentioned
• Not widely available in the speaker’s region/time (as said)

Clevidipine

• Mentioned as more used in emergency conditions
• Ultra-short half-life (~15 minutes mentioned)

---

D) Dosing / administration guidance presented

Nifedipine (DHP-CCB)

• Immediate-release

  • 10–20 mg three times daily

• Extended-release

  • 30–60 mg once daily
  • Maximum stated: 120 mg/day

• Key safety points emphasized

  • Risk of hypotension and acute tachycardia
  • Warned against using immediate-release for chronic management; extended-release preferred

Amlodipine

• Start: 5 mg
• If no improvement after a period (2 months mentioned):
  • Increase to 10 mg max
• Framed as suitable for chronic once-daily use due to long duration

Administration timing for hypertension (“chronopharmacology” as described)

• General idea: when to take meds depends on patient pattern

  • Diurnal (“morning”) preference for some patients
    • Speaker mentions “under 55 years” typically morning
  • Night dosing preference for others
    • Speaker mentions “over 55 years” / non-dipping pattern being high at night

• Amlodipine framed as flexible:

  • Can be taken either time due to long duration (~30 hours mentioned)

---

E) Side effects: categorized and explained

The video groups side effects into: Major, Moderate, and Minor.

Major side effects (major CCB problems)

Severe hypotension

• Especially with dihydropyridines, particularly immediate-release nifedipine
• Described cause:
  • Aggressive vasodilation → reduced blood pressure
• Suggested approach:
  • Use extended-release
  • Avoid crushing extended-release forms
  • Dosing strategies suggested to reduce hypotension risk

Tachycardia / reflex tachycardia

• Explained as a compensatory response after a rapid blood pressure drop
• Suggested management:
  • Combine with beta blockers (example given: atenolol)

---

Moderate side effects

Peripheral edema / swelling

• Mechanism described:
  • CCBs dilate arteries more than veins
  • Increased arterial volume space → fluid shift out of vessels → edema
• Timing described:
  • Often appears within 1–2 weeks
• Management steps mentioned:
  • Consider taking the medication in the morning
  • Encourage leg movement/activity, especially if swelling occurs overnight
  • If significant:
    • Switch therapy to an ACE inhibitor or ARB (examples implied: drugs ending in -pril or -sartan)

---

Minor side effects

Dizziness / faintness

• Explained as reduced cerebral perfusion after vasodilation
• Advice:
  • Stand up slowly

Constipation

• Explanation:
  • CCBs block calcium influx → reduce intestinal smooth muscle contraction → constipation
• Management:
  • Increase water intake
  • Increase fiber
  • Supportive options like yogurt/probiotics or fiber supplements

GERD (reflux-related discomfort)

• Claimed mechanism:
  • Calcium blockade weakens/impaired valve between stomach and esophagus → acid reflux
• Management suggested:
  • Antacids
  • H2 blockers
  • PPIs

---

F) Drug interactions: grouped by severity and described mechanisms

Major interactions

Grapefruit with amlodipine

• Mechanism described:
  • Grapefruit inhibits cytochrome P450
  • Amlodipine metabolism decreases → amlodipine levels rise
  • Increased risk of severe hypotension and side effects
• Instruction:
  • Do not take amlodipine with grapefruit during use

Non-dihydropyridines (diltiazem/verapamil) with beta-blockers

• Mechanism described:
  • Both reduce heart rate → synergistic effect
  • Risk: bradycardia and potentially cardiac arrest in worse cases
• Precautions mentioned:
  • ECG monitoring
  • Avoid combination when possible

Verapamil with digoxin

• Mechanism described:
  • Verapamil increases digoxin concentration
• Management:
  • Reduce digoxin dose if used together

---

Moderate interactions

CCB with NSAIDs

• Mechanism described:
  • NSAIDs reduce prostaglandin-mediated renal vasodilation → blunts CCB antihypertensive effect
• Practical suggestion:
  • Limit NSAID use or choose alternatives; if NSAIDs are necessary, keep duration short

---

Minor interactions

CCB with antacids

• Mechanism described:
  • Antacids bind CCB in the GI tract → lower absorption
• Management:
  • Separate doses by 2–4 hours

CCB with statins (especially simvastatin/lovastatin-type prodrugs)

• Mechanism described:
  • Some statins require activation via CYP3A4
  • Amlodipine inhibits CYP3A4 → statin levels rise → risk of muscle aches/myopathy
• Management:
  • Keep simvastatin dose around ≤20 mg (or avoid excessive dose increases)

---

Speakers / sources featured

• Only the video’s primary lecturer/speaker is present; no specific named expert/author is identified in the provided subtitles.